Daniel Perez, Hinge Health CEO: A Fortt Knox Update

Hinge Health CEO Dan Perez told Jon Fortt the company is launching a Migraine Care Program today, built around its FDA-cleared Enso wearable, now indicated for migraine via trigeminal-nerve neuromodulation. In trials, 56% of users dropped from moderate/severe pain to mild or no pain. The pitch: 1 in 6 adults, $78B in employer cost, only ~700 US specialists. 125 enterprise customers signed; ~2M American adults get day-one access. Earnings Tuesday.